Skip to main content
    E

    Entera Bio Ltd (ENTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.77
    +0.27 (+10.80%)

    Market Cap: $432.85M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(22/32)
    Avg Surprise
    -6.57%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.09 - $-0.05
    5 analysts
    EPS Revisions
    1
    0
    7d
    No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.08+15.0%
    60d ago$-0.08+15.0%
    30d ago$-0.08+15.0%
    7d ago$-0.08+15.0%
    Current$-0.07
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.29 - $-0.02
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 7
    		$-0.14$-0.08-75.00%Miss-133.3%
    Mar 26
    Reported May 8
    		$-0.07$-0.08+12.50%Beat-16.7%
    Dec 25
    Reported Mar 27
    		$-0.06$-0.11+45.45%Beat+0.0%
    Sep 25
    Reported Nov 14
    		$-0.07$-0.09+22.22%Beat+12.5%
    Jun 25
    Reported Aug 8
    		$-0.06$-0.11+45.45%Beat+0.0%
    Mar 25
    Reported May 9
    		$-0.06$-0.07+14.29%Beat-20.0%
    Dec 24
    Reported Mar 28
    		$-0.06$-0.08+25.00%Beat+14.3%
    Sep 24
    Reported Nov 8
    		$-0.08$-0.05-60.00%Miss+0.0%
    Jun 24
    Reported Aug 9
    		$-0.06$-0.06+0.00%Beat+25.0%
    Mar 24
    Reported May 10
    		$-0.05$-0.06+16.67%Beat+37.5%
    Dec 23
    Reported Mar 8
    		$-0.07$-0.08+12.50%Beat+30.0%
    Sep 23
    Reported Nov 14
    		$-0.08$-0.09+11.11%Beat+27.3%
    Jun 23
    Reported Aug 11
    		$-0.08$-0.07-14.29%Miss+27.3%
    Mar 23
    Reported May 5
    		$-0.08$-0.12+33.33%Beat+38.5%
    Dec 22
    Reported Mar 27
    		$-0.10$-0.11+9.09%Beat+52.4%
    Sep 22
    Reported Nov 10
    		$-0.11$-0.13+15.38%Beat-120.0%
    Jun 22
    Reported Aug 11
    		$-0.11$-0.16+31.25%Beat+47.6%
    Mar 22
    Reported May 12
    		$-0.13$-0.18+27.78%Beat+69.8%
    Dec 21
    Reported Mar 8
    		$-0.21$-0.23+8.70%Beat-61.5%
    Sep 21
    Reported Nov 10
    		$-0.05N/A+54.55%Beat+44.4%
    Jun 21
    Reported Aug 16
    		$-0.21$-0.12-75.00%Miss-23.5%
    Mar 21
    Reported May 20
    		$-0.43$-0.12-258.33%Miss-368.7%
    Dec 20
    Reported Mar 18
    		$-0.13$-0.14+7.14%Beat+50.0%
    Sep 20
    Reported Nov 19
    		$-0.09N/A+55.00%Beat+64.0%
    Jun 20
    Reported Aug 20
    		$-0.17$-0.12-41.67%Miss-41.7%
    Mar 20
    Reported May 21
    		$0.16$0.00N/ABeat+161.5%
    Dec 19
    Reported Mar 26
    		$-0.26$-0.19-36.84%Miss-52.9%
    Sep 19
    Reported Nov 21
    		$-0.25$-0.15-66.67%Miss+44.4%
    Jun 19
    Reported Aug 20
    		$-0.12N/A+57.14%Beat+25.0%
    Mar 19
    Reported Jun 27
    		$-0.26$0.00N/ABeat-225.0%
    Dec 18
    Reported Jan 22
    		$-0.17N/A+51.43%Beat+45.2%
    Sep 18
    Reported Sep 30
    		$-0.45$-0.28-60.71%Miss-136.8%
    Jun 18
    Reported Aug 20
    		$-0.16$-0.09-77.78%Miss-23.1%
    Mar 18
    Reported Jun 29
    		$-0.08$-0.08+0.00%Beat-14.3%
    Dec 17
    Reported Mar 30
    		$-0.31$0.00N/AMiss-
    Sep 17
    Reported Nov 9
    		$-0.19$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.13$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-0.07$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.15EV/EBITDAN/A
    Price/FCF-12.75xFCF Yield-7.84%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-138.90%ROIC-173.65%
    Financial Health
    Debt/Equity0.07xInterest CoverageN/A
    Current Ratio8.98xQuick Ratio8.98x
    Trading Statistics
    Beta1.41Avg Volume625.96K
    52-Week High$4.2052-Week Low$0.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.61
    SMA 20$2.73
    SMA 50$2.88
    SMA 200$1.84
    EMA 10$2.64
    EMA 20$2.70
    EMA 50$2.69
    EMA 200$2.16

    MACD

    Line: -0.07Signal: -0.07Hist: -0.01

    ADX

    ADX: 13.6+DI: 28.7-DI: 22.6

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down92.0
    PSAR$2.44

    Bollinger Bands

    Upper Band$3.06
    Lower Band$2.39
    %B Position2461%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    51.8

    Momentum Oscillators

    Stoch %K26.8
    Stoch %D24.3
    Williams %R-40.7
    ROC (10d)-4.2%
    Momentum-0.12
    CCI (20d)-20.5
    MFI (14d)47.9

    Volatility Measures

    ATR (14d)$0.19(7.0%)
    StdDev (20d)0.17
    Hist Vol71.9%(High)

    Volume Flow

    VWAP$2.69
    OBV132.0M
    AD Line6.8M
    CMF (20d)-0.116

    Volume Metrics

    Avg Vol (20d)634.2K
    Vol Ratio2.3x(High)
    VWMA (20d)$2.70

    Pivot Points

    R3$2.66
    R2$2.61
    R1$2.56
    Pivot Point$2.51
    S1$2.45
    S2$2.40
    S3$2.35

    Advanced Oscillators

    TSI-13.79
    Ultimate Osc51.0
    KST-109.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$42,000$82,000$42,000$57,000$0$4.48M$0
    Cost of Revenue$0$0$7,000$0$0$42,000$82,000$42,000$48,000$0$13,000$0
    Gross Profit$0$0$-7,000$0$0$0$0$0$9,000$0$-13,000$0
    Operating Expenses$4.56M$3.54M$3.04M$3.26M$2.67M$2.56M$2.34M$3.02M$2.17M$2.06M$1.94M$2.39M
    R&D$3.20M$2.25M$1.72M$1.64M$1.52M$1.12M$1.20M$1.48M$1.09M$735,000$1.00M$1.37M
    SG&A$1.36M$1.29M$1.32M$1.61M$1.15M$1.44M$1.14M$1.54M$1.09M$1.33M$973,000$1.03M
    Operating Income$-4,563,000$-3,539,000$-3,042,000$-3,256,000$-2,668,000$-2,563,000$-2,337,000$-3,021,000$-2,165,000$-2,062,000$-1,963,000$-2,386,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.75M$0$0$0$0$4,000$7,000$0$0$0$32,000$0
    Income Before Tax$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,344,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,350,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$29,000
    Net Income$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,358,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,379,000
    EBITDA$-7,303,000$-3,498,000$-3,009,000$-3,192,000$-2,649,000$-2,559,000$-2,333,000$-3,010,000$-2,134,000$-2,004,000$-1,982,000$-2,336,000
    EBIT$-7,312,000$-3,505,000$-3,016,000$-3,200,000$-2,656,000$-2,567,000$-2,344,000$-3,021,000$-2,145,000$-2,017,000$-1,995,000$-2,350,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENTX

    News

    Quick ratio of Entera Bio Ltd. – HAN:5DT

    This article provides financial information for Entera Bio Ltd. (HAN:5DT) on the Hannover Stock Exchange, specifically focusing on its quick ratio. It is presented through the TradingView platform...

    TradingView•10/14/26•Neutral

    Form DEF 14A ENTERA BIO LTD. For: 14 October By Investing.com

    This article announces the filing of Form DEF 14A by ENTERA BIO LTD. on October 14. The filing is related to the company's activities as of that date. The article is very brief and primarily serves as a notification...

    Investing.com Canada•10/14/26•Neutral

    Entera Bio presents phase 2 data for oral osteoporosis drug

    Entera Bio Ltd. presented positive Phase 2 trial data for its oral osteoporosis drug, EB613, at the American Society for Bone and Mineral Research 2026 Annual Meeting. The study showed significant bone mineral density...

    Investing.com•10/13/26•Bullish

    Entera Presents Markedly Enhanced Anabolic Effects of EB613

    Entera Bio Ltd. announced enhanced anabolic effects of its experimental drug EB613, an oral PTH(1-34) tablet, for postmenopausal women with osteoporosis at high risk of fracture. Post-hoc Phase 2 data revealed greater...

    GlobeNewswire•10/13/26•Bullish

    A planned trial will test an osteoporosis pill in about 900 women

    Entera Bio presented exploratory Phase 2 results for its oral osteoporosis drug, EB613, showing enhanced anabolic effects in postmenopausal women with osteoporosis. The company also unveiled the design for its planned...

    Stock Titan•10/13/26•Somewhat-Bullish

    ENTX Valuation and Fair Value

    P/E
    -8.1x
    P/FCF
    -12.7x
    P/B
    19.2x
    See GNG's fair value

    ENTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -173.6%
    ROE
    -138.9%
    FCF yield
    -7.8%

    ENTX Competitors

    CompanyTicker
    XOMA Royalty CorporationXOMAP
    Neuropace IncNPCE
    XOMA CorporationXOMAO
    Prothena Corporation plcPRTA
    Alpha Teknova IncTKNO
    Cross Country Healthcare IncCCRN
    Oculis Holding AG Ordinary sharesOCS
    Ovid Therapeutics IncOVID

    Sector: Healthcare

    ENTX Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ENTX Bull Case vs Bear Case

    Bull case

    • ENTX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of ENTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • ENTX's quarterly revenue changed -100.0% year over year.

    ENTX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    3.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About ENTX

    Does ENTX pay dividends?

    Entera Bio Ltd (ENTX) does not currently pay a regular dividend.

    What is ENTX's market cap?

    Entera Bio Ltd (ENTX) has a market capitalization of $432.85M with a current stock price of $2.77.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In